The antiserum was produced against synthesized peptide derived from human AKR1C3. AA range:191-240

DD3 Polyclonal Antibody detects endogenous levels of DD3 protein.

AKR1C3

Aldo-keto reductase family 1 member C3

AKR1C3 ;
DDH1 ;
HSD17B5 ;
KIAA0119 ;
PGFS ;
Aldo-keto reductase family 1 member C3 ;
17-beta-hydroxysteroid dehydrogenase type 5 ;
17-beta-HSD 5 ;
3-alpha-HSD type II ;
brain ;
3-alpha-hydroxysteroid dehydrogenase type 2 ;
3-alpha-HSD type 2 ;
Chlordec

This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ), and the oxidation of 9alpha,11beta-PGF2 to PGD2. It may play an important role in the pathogenesis of allergic diseases such as asthma, and may also have a role in controlling cell growth and/or differentiation. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2011],

Catalytic activity:(5Z,13E)-(15S)-9-alpha,11-alpha,15-trihydroxyprosta-5,13-dienoate + NADP(+) = (5Z,13E)-(15S)-9-alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH.,Catalytic activity:Androsterone + NAD(P)(+) = 5-alpha-androstane-3,17-dione + NAD(P)H.,Catalytic activity:Indan-1-ol + NAD(P)(+) = indanone + NAD(P)H.,Catalytic activity:Testosterone + NAD(+) = androst-4-ene-3,17-dione + NADH.,Catalytic activity:Testosterone + NADP(+) = androst-4-ene-3,17-dione + NADPH.,Catalytic activity:Trans-1,2-dihydrobenzene-1,2-diol + NADP(+) = catechol + NADPH.,enzyme regulation:Strongly inhibited by nonsteroidal anti-inflammatory drugs (NSAID) including flufenamic acid and indomethacin. Also inhibited by the flavinoid, rutin, and by selective serotonin inhibitors (SSRIs).,Function:Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.,similarity:Belongs to the aldo/keto reductase family.,tissue specificity:Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. The dominant HSD in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate.,

Cytoplasm .

Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. High expression in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate.

>>Steroid hormone biosynthesis ;
>>Arachidonic acid metabolism ;
>>Folate biosynthesis ;
>>Metabolic pathways ;
>>Ovarian steroidogenesis ;
>>Chemical carcinogenesis - reactive oxygen species